Condition
t(11;14) Positive
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07335887Phase 2Not Yet Recruiting
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
NCT03872180Phase 2Active Not Recruiting
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Showing all 2 trials